Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT01180543 Completed - Acne Vulgaris Clinical Trials

Acne Treatment With Active Oplon's Patches

Start date: August 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.

NCT ID: NCT01179633 Completed - Acne Vulgaris Clinical Trials

Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid

Start date: March 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.

NCT ID: NCT01176955 Completed - Acne Vulgaris Clinical Trials

A Novel Method to Improve Acne Outcomes

Start date: May 2009
Phase: N/A
Study type: Interventional

This is an investigator-blinded, prospective study of 20 subjects aged 13 through 18 with mild to moderate acne. Study subjects will be randomized to an internet survey group, in which an email link for a survey ascertaining the status of the subject's acne is sent weekly, or to a control group. All study subjects will use benzoyl peroxide 5% gel, and adherence and clinical improvement will be monitored over 12 weeks. The investigators hypothesis is that subjects in the internet survey group will have improved adherence to the study medication and clinical outcomes, because the weekly survey will remind subjects to use their medication.

NCT ID: NCT01160848 Completed - Acne Vulgaris Clinical Trials

Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients

Start date: August 2010
Phase: Phase 2
Study type: Interventional

Open, prospective, randomized, single-centre study in patients with moderate to severe facial acne vulgaris. Three circular areas with a diameter of 4 cm, each circle including at least 4 inflammatory lesions, will be selected in acne-affected areas in the face. One area should be identified on each cheek and one area should be identified on the forehead. The minimum distance between the three areas should be at least 4 cm. For each patient the three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application. After the last fluorescence spectroscopy reading, the cream should be wiped off and the patient should protect the three areas from sunlight, prolonged, or intense light for 2 days. The study was extended with additionally 8 patients to explore the photoactive porphyrin levels over a 24 hour period: The patients will clean their face with Cetaphil Gentle Skin Cleanser before cream application. For each patient the three areas will be randomized to Visonac 80mg left on the skin for 24 hours and Visonac (MAL8%) to be wiped of after 1 hour. In vivo fluorescence spectroscopy will be performed at all three areas before cream application, and at 2h, 3 h, 4h, 5h, 8h, 10h, 11h, 12h, 13h, 15 and 24h after cream application. The exact time points may be adjusted based on the result from the previously included patients. All patients will be instructed to protect the three areas from sunlight, prolonged, or intense light for 2 days.

NCT ID: NCT01160757 Completed - Acne Vulgaris Clinical Trials

A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions

Start date: October 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out how effective and safe an experimental ultrasound device is for treating Acute Acne lesions.

NCT ID: NCT01149330 Completed - Acne Vulgaris Clinical Trials

Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris

Estudo Epiduo
Start date: July 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate the efficacy of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the treatment of acne vulgaris. The safety will also be evaluated.

NCT ID: NCT01138735 Completed - Acne Clinical Trials

Epiduo Pediatric Acne Study

Start date: June 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.

NCT ID: NCT01138514 Completed - Acne Vulgaris Clinical Trials

Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels

Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).

NCT ID: NCT01132443 Completed - Acne Vulgaris Clinical Trials

W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne

Start date: May 6, 2010
Phase: Phase 1
Study type: Interventional

This study was conducted to determine if the bioavailability of clindamycin and its metabolite clindamycin sulfoxide are altered by the concentration of BPO or the absence of methylparaben. This study compared the investigational study product and 2 marketed products: - CLN 1%-BPO 3% Gel (clindamycin 1%-BPO 3%), methylparaben-free - Topical Gel (clindamycin 1%-BPO 5%), methylparaben-preserved (Topical Gel-MP) - Once Daily Gel ((clindamycin 1%-BPO 5%), methylparaben-free (Topical Gel-MPF)

NCT ID: NCT01119651 Completed - Acne Vulgaris Clinical Trials

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

Start date: June 14, 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a photoallergic reaction when exposed to UV and VIS light on skin of healthy volunteers.